Literature DB >> 18475474

Interleukin-6 in peripheral blood and inflammatory sites in Behçet's disease.

K Hamzaoui1, A Hamzaoui, A Kahan, M Hamza, A Chabbou, K Ayed.   

Abstract

Interleukin-6, a potent pro-inflammatory cytokine, might be involved in Behçet's disease (BD) pathological pathways. We investigated IL-6 levels in sera and synovial fluids collected from BD patients. The IL-6 production was also studied in vivo, by measuring its activity in culture supernatants of PBMC and alveolar macrophages, stimulated or not with LPS. The patients with BD were compared to RA patients and healthy controls. High IL-6 levels were observed in sera, synovial fluid and LPS stimulated PBMC supernatants, from active BD patients, similar to those of RA patients. Alveolar macrophages production of IL-6 was significantly elevated in two active BD patients with an interstitial pneumonia, when compared to controls. These elevated levels of IL-6 suggest its involvement in the inflammatory sites of BD, which may be related to the progression of the acute lesions, at least in the joints and in the lungs.

Entities:  

Year:  1992        PMID: 18475474      PMCID: PMC2365351          DOI: 10.1155/S0962935192000437

Source DB:  PubMed          Journal:  Mediators Inflamm        ISSN: 0962-9351            Impact factor:   4.711


  23 in total

1.  Production of TNF-alpha and IL-1 in active Behçet's disease.

Authors:  K Hamzaoui; M Hamza; K Ayed
Journal:  J Rheumatol       Date:  1990-10       Impact factor: 4.666

Review 2.  Determinants of immune cell trafficking in the skin.

Authors:  L J Walsh; R M Lavker; G F Murphy
Journal:  Lab Invest       Date:  1990-11       Impact factor: 5.662

3.  Monocyte-derived human B-cell growth factor identified as interferon-beta 2 (BSF-2, IL-6).

Authors:  G Tosato; K B Seamon; N D Goldman; P B Sehgal; L T May; G C Washington; K D Jones; S E Pike
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

4.  Cytotoxic T cells against herpes simplex virus in Behçet's disease.

Authors:  K Hamzaoui; A Kahan; K Ayed; M Hamza
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

5.  Soluble interleukin 2 receptors in patients with Behçet's disease.

Authors:  K Hamzaoui; K Ayed
Journal:  J Rheumatol       Date:  1989-06       Impact factor: 4.666

6.  Multiple actions of interleukin 6 within a cytokine network.

Authors:  G G Wong; S C Clark
Journal:  Immunol Today       Date:  1988-05

7.  Constitutive production of interleukin 6/B cell stimulatory factor-2 from inflammatory synovium.

Authors:  N Miyasaka; K Sato; J Hashimoto; H Kohsaka; K Yamamoto; M Goto; K Inoue; T Matsuda; T Hirano; T Kishimoto
Journal:  Clin Immunol Immunopathol       Date:  1989-08

Review 8.  Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.

Authors:  W P Arend; J M Dayer
Journal:  Arthritis Rheum       Date:  1990-03

9.  Augmented interleukin-1 production and HLA-DR expression in the synovium of rheumatoid arthritis patients. Possible involvement in joint destruction.

Authors:  N Miyasaka; K Sato; M Goto; M Sasano; M Natsuyama; K Inoue; K Nishioka
Journal:  Arthritis Rheum       Date:  1988-04

10.  Soluble cytokine receptors are present in normal human urine.

Authors:  D Novick; H Engelmann; D Wallach; M Rubinstein
Journal:  J Exp Med       Date:  1989-10-01       Impact factor: 14.307

View more
  2 in total

1.  Immunometabolic biomarkers of inflammation in Behçet's disease: relationship with epidemiological profile, disease activity and therapeutic regimens.

Authors:  L Cantarini; V Pucino; A Vitale; R Talarico; O M Lucherini; F Magnotti; V De Rosa; M Galgani; C Alviggi; G Marone; M Galeazzi; G Matarese
Journal:  Clin Exp Immunol       Date:  2016-02-24       Impact factor: 4.330

Review 2.  The Roles of Monocytes and Macrophages in Behçet's Disease With Focus on M1 and M2 Polarization.

Authors:  Lisa Hirahara; Kaoru Takase-Minegishi; Yohei Kirino; Yuki Iizuka-Iribe; Yutaro Soejima; Ryusuke Yoshimi; Hideaki Nakajima
Journal:  Front Immunol       Date:  2022-03-11       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.